{
    "clinical_study": {
        "@rank": "16749", 
        "arm_group": {
            "arm_group_label": "spliceosome", 
            "description": "patient who have available data for spliceosome mutation status"
        }, 
        "biospec_descr": {
            "textblock": "Genomic DNA extracted from bone marrow aspirate"
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "In the era of hypomethylating agent in MDS treatment, the investigators aimed to investigate\n      the prognostic impact of mutations in spliceosome machinery genes (SRSF2, U2AF1, and ZRSR2)\n      on the outcomes of 1st line decitabine treatment in MDS."
        }, 
        "brief_title": "Prognostic Molecular Markers in Patients With Myelodysplastic Syndrome", 
        "completion_date": {
            "#text": "February 2014", 
            "@type": "Actual"
        }, 
        "condition": "Myelodysplastic Syndrome", 
        "condition_browse": {
            "mesh_term": [
                "Myelodysplastic Syndromes", 
                "Preleukemia"
            ]
        }, 
        "detailed_description": {
            "textblock": "A number of studies have tried to investigate clinical impact of mutations in spliceosomal\n      machinery genes in MDS but they failed to demonstrate a consistent prognostic relevance.\n      Moreover, the clinical impact of these mutations on the outcomes of hypomethylating agent\n      treatment in MDS has never been explored yet. The investigators investigated the prognostic\n      impact of mutations in spliceosome machinery genes (SRSF2, U2AF1, and ZRSR2) on the outcomes\n      of 1st line decitabine treatment in MDS."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  de novo MDS patients were included in the study who had received 1st line decitabine\n             treatment and had adequate genomic DNA from pretreated bone marrow samples\n\n        Exclusion Criteria:\n\n          -  therapy-related MDS"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "90 Years", 
            "minimum_age": "17 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "de novo MDS patients were included in the study who had received 1st line decitabine\n        treatment and had adequate genomic DNA from pretreated bone marrow samples"
            }
        }, 
        "enrollment": {
            "#text": "58", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 10, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02060409", 
            "org_study_id": "2012-01-081-003"
        }, 
        "intervention": {
            "arm_group_label": "spliceosome", 
            "description": "spliceosome mutations", 
            "intervention_name": "spliceosome", 
            "intervention_type": "Genetic"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "myelodysplastic syndrome", 
            "decitabine", 
            "spliceosome mutation"
        ], 
        "lastchanged_date": "February 11, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of"
                }, 
                "name": "Samsung Medical Center"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_groups": "1", 
        "official_title": "Prognostic Molecular Markers Determined by Using Gene Expression Profiling in Patients With Myelodysplastic Syndrome", 
        "overall_official": {
            "affiliation": "Samsung Medical Center", 
            "last_name": "Jun Ho Jang, MD PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Korea: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "overall survival", 
            "safety_issue": "No", 
            "time_frame": "Two years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02060409"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Samsung Medical Center", 
            "investigator_full_name": "Jun Ho Jang", 
            "investigator_title": "Jun Ho Jang", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Samsung Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Samsung Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2012", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Retrospective", 
        "study_type": "Observational", 
        "verification_date": "February 2014"
    }
}